Mereo BioPharma Group PLC
MREO1.690USD
-1.250-42.52%
收盤 07/10, 16:00（美東）報價延遲15分鐘
1.34B總市值
虧損本益比TTM
關於 Mereo BioPharma Group PLC 公司
Mereo BioPharma Group plc 是一家專注於開發罕見病治療藥物的生物製藥公司。該公司已開發了一系列後期臨牀候選產品，其兩種罕見病候選產品是用於治療成骨不全症 (OI) 的 setrusumab 和主要用於治療嚴重 α-1 抗胰蛋白酶缺乏症相關肺病 (AATD-LD) 的 alvelestat。除了罕見病項目外，該公司還有兩種腫瘤候選產品處於臨牀開發階段。Etigilimab 是一種 IgG1 單克隆抗體，可與免疫細胞上具有 Ig 和 ITIM 結構域 (TIGIT) 受體的人類 T 細胞免疫受體結合，以提高 T 細胞和 NK 細胞抗腫瘤活性的激活和有效性。Navicixizumab 是一種雙特異性抗體，可抑制 delta 樣配體 4 (DLL4) 和血管內皮生長因子 (VEGF)。Navicixizumab 被開發用於治療晚期卵巢癌。
公司簡介
公司代碼MREO
公司名稱Mereo BioPharma Group PLC
上市日期Jun 09, 2016
成立日期2015
CEODr. Denise V. Scots-Knight, Ph.D.
員工數量36
證券類型Depository Receipt
年結日Jun 09
公司地址One Cavendish Place
城市LONDON
上市交易所NASDAQ Capital Market Consolidated
國家United Kingdom
郵編W1G0QF
電話443330237300
網址https://www.mereobiopharma.com/
公司代碼MREO
上市日期Jun 09, 2016
成立日期2015
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Ms. Alexandra (Wills) Hughes-Wilson
Ms. Alexandra (Wills) Hughes-Wilson
Chief Patient Access and Commercial Planning
Chief Patient Access and Commercial Planning
94.77K
+174.32%
Dr. John A. Lewicki, Ph.D.
Dr. John A. Lewicki, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
78.63K
+61.20%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
25.05K
--
Dr. Jeremy Bender, Ph.D.
Dr. Jeremy Bender, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
12.55K
--
Dr. Deepika R. Pakianathan, Ph.D.
Dr. Deepika R. Pakianathan, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Justin Roberts
Mr. Justin Roberts
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Charles E. Sermon
Mr. Charles E. Sermon
General Counsel and Business Development, Company Secretary
General Counsel and Business Development, Company Secretary
--
--
Dr. Anders Ekblom, M.D., Ph.D.
Dr. Anders Ekblom, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Christine Fox
Ms. Christine Fox
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Alexandra (Wills) Hughes-Wilson
Ms. Alexandra (Wills) Hughes-Wilson
Chief Patient Access and Commercial Planning
Chief Patient Access and Commercial Planning
94.77K
+174.32%
Dr. John A. Lewicki, Ph.D.
Dr. John A. Lewicki, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
78.63K
+61.20%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
25.05K
--
Dr. Jeremy Bender, Ph.D.
Dr. Jeremy Bender, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
12.55K
--
Dr. Deepika R. Pakianathan, Ph.D.
Dr. Deepika R. Pakianathan, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Justin Roberts
Mr. Justin Roberts
Non-Executive Independent Director
Non-Executive Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 6月14日 週六
更新時間: 6月14日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Janus Henderson Investors
14.30%
Rubric Capital Management LP
9.63%
Northpond Ventures, LLC
6.86%
Mangrove Partners
5.43%
Frazier Life Sciences Management, L.P.
5.08%
Other
58.71%
持股股東
持股股東
佔比
Janus Henderson Investors
14.30%
Rubric Capital Management LP
9.63%
Northpond Ventures, LLC
6.86%
Mangrove Partners
5.43%
Frazier Life Sciences Management, L.P.
5.08%
Other
58.71%
股東類型
持股股東
佔比
Hedge Fund
36.01%
Investment Advisor/Hedge Fund
19.61%
Venture Capital
6.86%
Private Equity
5.63%
Investment Advisor
5.13%
Research Firm
3.10%
Individual Investor
0.86%
Bank and Trust
0.23%
Other
22.57%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
167
123.11M
77.43%
-2.93M
2025Q1
176
112.84M
70.99%
-23.15M
2024Q4
174
116.69M
75.21%
-16.90M
2024Q3
167
107.29M
69.42%
-17.56M
2024Q2
164
101.82M
66.22%
-5.20M
2024Q1
162
84.96M
60.56%
-41.79M
2023Q4
143
78.69M
56.11%
-37.03M
2023Q3
141
72.18M
51.57%
-33.53M
2023Q2
149
64.87M
50.46%
-34.19M
2023Q1
152
61.46M
49.21%
-39.78M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Janus Henderson Investors
22.74M
14.3%
+5.61M
+32.78%
Mar 31, 2025
Rubric Capital Management LP
15.31M
9.63%
--
--
Mar 31, 2025
Northpond Ventures, LLC
10.90M
6.86%
+10.90M
--
Jun 04, 2025
Mangrove Partners
8.64M
5.43%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
8.07M
5.08%
+250.00K
+3.20%
Apr 01, 2025
Deerfield Management Company, L.P.
6.71M
4.22%
--
--
Mar 31, 2025
Rock Springs Capital Management LP
6.68M
4.2%
-2.91M
-30.37%
Mar 31, 2025
Alkeon Capital Management LLC
4.70M
2.95%
--
--
Mar 31, 2025
683 Capital Management LLC
4.63M
2.92%
+85.00K
+1.87%
Mar 31, 2025
Clearline Capital LP
3.22M
2.02%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 7月6日 週日
更新時間: 7月6日 週日
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.91%
iShares Genomics Immunology and Healthcare ETF
0.88%
Tema Oncology ETF
0.47%
Tema Heart & Health ETF
0.45%
SPDR S&P International Small Cap ETF
0.02%
ActivePassive International Equity ETF
0%
Formidable ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.91%
iShares Genomics Immunology and Healthcare ETF
佔比0.88%
Tema Oncology ETF
佔比0.47%
Tema Heart & Health ETF
佔比0.45%
SPDR S&P International Small Cap ETF
佔比0.02%
ActivePassive International Equity ETF
佔比0%
Formidable ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
